Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
LYEL Lyell Immunopharma
3.340+0.060+1.83%
Close
01/27 16:00 ET
3.480+0.140+4.19%
Post Mkt Price 01/27 18:58 ET
High
3.392
Open
3.260
Turnover
1.79M
Low
3.220
Pre Close
3.280
Volume
539.19K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Hilltop GAAP EPS of $0.39, Revenue of $169.78M
BAND, PRTK and OTLY Are Among After Hour Movers
Lyell Immunopharma (NASDAQ:LYEL) PT Lowered to $4.00 at Morgan Stanley
Lyell Immunopharma (NASDAQ:LYEL – Get Rating) had its price target trimmed by Morgan Stanley from $7.00 to $4.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently has
Morgan Stanley Adjusts Lyell Immunopharma's Price Target to $4 From $7, Maintains Equal Weight Rating
11:38 AM EST, 01/24/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Morgan Stanley Sticks to Its Hold Rating for Lyell Immunopharma (LYEL)
Lyell Immunopharma Is Maintained at Equal-Weight by Morgan Stanley
Lyell Immunopharma Price Target Cut to $4.00/Share From $7.00 by Morgan Stanley
Lyell Immunopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/24/2023 34.23% Morgan Stanley $7 → $4 Maintains Equal-Weight 11/14/2022 134.9% Morgan Stanley $15 → $7
Morgan Stanley Maintains Equal-Weight on Lyell Immunopharma, Lowers Price Target to $4
Morgan Stanley analyst Matthew Harrison maintains Lyell Immunopharma (NASDAQ:LYEL) with a Equal-Weight and lowers the price target from $7 to $4.
Insiders Are Probably Glad They Sold Their Shares in Lyell Immunopharma, Inc. (NASDAQ:LYEL) After 7.4% Drop
Insiders seem to have made the most of their holdings by selling US$71k worth of Lyell Immunopharma, Inc. (NASDAQ:LYEL) stock at an average sell price of US$6.40 during the past year. After the stock
Company Overview
More
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
CEO： Dr. Lynn Seely,M.D.
Market： NASDAQ
Listing Date： 06/17/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet